3-Methylglutaconic Acid

If you have unexplained muscle weakness, neurological symptoms, fatigue that defies a standard workup, or a family history of a rare metabolic condition, this test can point to a category of problems that routine blood panels are not designed to catch. It is a urinary marker that shows up when something is off with how your cells generate energy or process the amino acid leucine.

In healthy people, this acid appears in only trace amounts. Persistent elevation is a flag for an inborn error of metabolism or mitochondrial disorder, and even when it is not diagnostic on its own, it tells your clinician where to look next.

What This Marker Actually Measures

3-MGA (3-methylglutaconic acid) is a small organic acid produced as an intermediate in two cellular processes: the breakdown of the amino acid leucine, and a side branch of the pathway your cells use to make cholesterol and related molecules. Both pathways run through the mitochondria, the energy-producing compartments inside your cells. When mitochondrial machinery or leucine processing is disrupted, this acid accumulates and is excreted in urine.

In healthy individuals, levels are minimal. In people with a condition that disturbs these pathways, levels can climb many times higher than baseline. The acid itself is not harmful in the amounts typically seen. It is a signal, not a toxin.

Inborn Errors of Leucine Metabolism

The clearest disease association is with 3-methylglutaconic aciduria type I, caused by a defect in the AUH gene that encodes an enzyme called 3-methylglutaconyl-CoA hydratase. This enzyme normally helps break down leucine inside mitochondria. When it is missing or impaired, 3-MGA builds up. Levels in this condition are typically high and persistent, and they rise further after a protein-rich meal.

The clinical picture of this condition spans a wide range, from people who are essentially without symptoms to those with slowly progressive neurological problems including ataxia (loss of muscle coordination), cognitive impairment, and white-matter changes on brain imaging that often appear in adulthood. The biochemistry, a marked rise in 3-MGA along with related metabolites called 3-methylglutaric acid and 3-hydroxyisovaleric acid, is what points to the diagnosis.

Mitochondrial Disorders

3-MGA is one of the more informative urinary markers of mitochondrial dysfunction. In a large series of patients referred for suspected metabolic disease, about 3% of all samples showed elevated 3-MGA. Among patients with genetically confirmed mitochondrial disorders, roughly 11% showed this pattern, and the rate was higher in those with ATP-synthase-related disorders or mitochondrial DNA depletion syndromes.

Several specific genetic conditions use 3-MGA as a discriminative biochemical feature. These include Barth syndrome (caused by TAZ mutations, which produces cardiomyopathy, skeletal muscle weakness, and low neutrophil counts), MEGDEL syndrome (SERAC1 mutations, with deafness, dystonia, and encephalopathy), Costeff syndrome (OPA3, with optic atrophy and movement disorder), and disorders caused by mutations in DNAJC19, TMEM70, CLPB, TIMM50, and YME1L1. Each presents with its own combination of cardiomyopathy, cataracts, neutropenia (low neutrophil counts), lactic acidosis, seizures, or developmental issues.

Beyond these named syndromes, elevated 3-MGA also appears in a broader group of mitochondrial disorders where it is not diagnostic by itself, but signals that something is wrong with mitochondrial membrane or energy-production machinery. In a study of patients with muscle respiratory chain defects, urinary organic acid testing was abnormal in most cases.

Other Conditions That Can Raise This Marker

Elevated 3-MGA has also been reported in:

• Organic acidurias, urea cycle disorders, and fatty-acid oxidation defects: other inherited metabolic conditions where 3-MGA is a non-specific secondary finding.
• Glycogen storage disorders: including type Ia, where mitochondrial impairment can produce mild elevations.
• Smith-Lemli-Opitz syndrome: a disorder of cholesterol biosynthesis where defective sterol production appears to spill into the related 3-MGA pathway.
• Pregnancy and congenital adrenal hyperplasia: physiological or hormonal states that can raise excretion through steroid synthesis byproducts.

Why a Single Reading Can Be Misleading

Excretion of this acid can vary. Some classic 3-MGA syndromes, including Barth syndrome and Pearson marrow-pancreas syndrome, can occur without elevated 3-MGA in a given urine sample. A single normal result does not rule out these conditions if clinical suspicion is high.

There are several common sources of misinterpretation:

• Protein-rich meals: in 3-MGA type I, a high-leucine meal in the hours before testing can substantially raise the result. This is sometimes used as a diagnostic provocation, but it can also distort baseline measurements.
• Intermittent excretion: in many mitochondrial syndromes, 3-MGA elevation comes and goes. A single negative result during a stable period can be falsely reassuring.
• Pregnancy: elevated excretion has been reported in pregnant women without underlying metabolic disease.
• Collection issues: because results are reported relative to creatinine, dilute or concentrated urine samples can shift values. Lab handling and the analytical method (gas chromatography-mass spectrometry, a technique for identifying small molecules) also affect comparability between labs.

Tracking Your Trend

This is a research and clinical marker without standardized reference cutoffs that apply across labs. A single isolated reading rarely settles a diagnosis. When the marker is elevated, repeat testing on a separate day, ideally in a fasted or controlled state, is the next step. The pattern over time, paired with other metabolites in the same urine sample, carries more weight than any single number.

If your initial result is elevated, retest within several weeks, then repeat at intervals while a full workup is in progress. If your initial result is normal but symptoms persist, repeat testing during a symptomatic episode can catch intermittent excretion that a routine sample misses.

Decision Pathway for Unexpected Results

An elevated result is the start of an investigation, not a diagnosis on its own. The next logical steps depend on context:

• Full urine organic acid profile: 3-MGA is rarely interpreted alone. The pattern of other organic acids in the same sample (3-methylglutaric, 3-hydroxyisovaleric, lactic acid, methylmalonic acid, and others) narrows the differential diagnosis substantially.
• Specialist referral: a metabolic geneticist or biochemical geneticist is the appropriate clinician to coordinate further workup. For specific syndromes, a cardiologist (for suspected Barth syndrome), a neurologist (for movement disorders, ataxia, or white-matter brain disease), or a hematologist (for unexplained low neutrophil counts) may also be involved.
• Genetic testing: depending on the suspected condition, targeted sequencing of AUH, TAZ, SERAC1, OPA3, DNAJC19, TMEM70, CLPB, or a broader mitochondrial gene panel may be ordered.
• Mitochondrial workup: measurements of blood lactate, plasma amino acids, acylcarnitine profile (a panel of fat-derived molecules), and in some cases muscle biopsy with respiratory chain enzyme assays may be needed to confirm mitochondrial dysfunction.

What this means for you: an elevated result that is reproduced on a repeat sample warrants a referral to a metabolic specialist. A single elevated result with normal companion metabolites and no clinical findings is often a non-specific signal that needs context before action.